8-K filed Nov 2, 2026 at 16:07 ET
BioMarin reported Q3 2026 total revenues of $1.025B, up 32% YoY, driven by the Amicus acquisition (GALAFOLD and POMBILITI+OPFOLDA) and 12% VOXZOGO growth. GAAP EPS was -$0.63 (vs consensus -$0.11), heavily impacted by $288M in acquired IPR&D charges and $99M in intangible amortization. Non-GAAP EPS was $0.23. Full-year 2026 revenue guidance was lowered to $3.80B-$3.90B (from $3.875B-$3.925B) due to order timing uncertainty, and Non-GAAP EPS guidance was slashed to $2.80-$3.10 (from $4.90-$5.10) reflecting the Alesta acquisition and BMN 450 license charges.